Pre-Immunization and Immunotherapy in HIV(+) Patients IL
Country:
Israel
Docket No:
436313-001191
Publication Number:
284348
Patent Expiry:
01/11/2037
Claims Scope:
Allowed. Issue fee paid. Awaiting patent certificate.
Sequence (and Gene) Agnostic Method Claims
Two sequence-specific guides
Two sequence-specific guide+backbone (corrected)
- Sequence agnostic method claim to CCR5 only, with a viral particle encoding a small RNA capable of inhibiting expression of CCR5
- Sequence agnostic method claim to HIV gene, with a viral particle encoding a small RNA capable of inhibiting expression of at least one HIV gene
- Two sequences with 80% identity to SIN 2, & 108 (mir21Vif, and corrected sequence mir185 Tat, any order) guide + backbone
- Two of three sequences with 80% identity to SIN 1, 2 and 108 (mir30 CCR5, mir21Vif, and corrected mir185Tat)
- Two of three sequences with 80% identity to SIN 97, 6 & & 7 (CCR5, Vif, and Tat, any order) guide only
- Compositions & methods (broadest method claims agnostic to pre-immunized state; dependent claims include pre-immunization)